Filling in the gaps in PARP inhibitor-induced synthetic lethality

Tumors with loss of breast cancer type 1 susceptibility protein (BRCA1) are homologous recombination (HR) deficient and hypersensitive to poly(ADP-ribose) polymerase inhibitors (PARPi). However, these tumors may restore HR and acquire PARPi resistance via loss of end-protection of DNA double-strand...

Full description

Saved in:
Bibliographic Details
Published in:Molecular & cellular oncology 2021, Vol.8 (6), p.2010512-2010512
Main Authors: Paes Dias, Mariana, Jonkers, Jos
Format: Article
Language:English
Subjects:
BRCA1/2
drug resistance
PARP inhibitors
ssDNA gaps
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Tumors with loss of breast cancer type 1 susceptibility protein (BRCA1) are homologous recombination (HR) deficient and hypersensitive to poly(ADP-ribose) polymerase inhibitors (PARPi). However, these tumors may restore HR and acquire PARPi resistance via loss of end-protection of DNA double-strand breaks. We found that loss of nuclear DNA ligase III resensitizes HR-restored BRCA1-deficient cells to PARPi by exposing post-replicative single-stranded DNA (ssDNA) gaps. Our work, and that of others, identifies ssDNA gaps as a key determinant of PARPi response.
ISSN:2372-3556
2372-3556
DOI:10.1080/23723556.2021.2010512